Episodes
- Friday, November 6, 2026 · 5 min Brazilian Court Halts Compounded Tirzepatide Program Serving 400
- Thursday, November 5, 2026 · 5 min Compounded Tirzepatide Ads Face a Reality Check
- Wednesday, November 4, 2026 · 8 min FDA Warns RonanRx Over 'FDA-Approved Compounded' GLP-1 Claims; New Zealand's Pharmac Still Isn't Funding Wegovy; Doctors Push Back on an Off-Label Estimate
- Tuesday, November 3, 2026 · 8 min Ohio's Medicaid Rulebook Bars GLP-1s for Obesity; An AHA Abstract Pits GLP-1s Against Metformin in Prediabetes; Australia Clears the Wegovy Pill
- Monday, November 2, 2026 · 8 min Novo and GoodRx Offer Employers a Side Door to GLP-1 Coverage; Korea's Obesity-Drug Demand and Smuggling Surge; Sun Pharma Wins India Nod for a Generic Semaglutide Pill
- Friday, October 30, 2026 · 8 min Medicare's GLP-1 Bridge Three Months In; Korea's Homegrown Eppe Reaches Clinics at a Lower Starting Price; Pooled Trials Link Semaglutide to Slower Kidney Decline
- Thursday, October 29, 2026 · 7 min Lilly Says Retatrutide Beat Ozempic Head-to-Head; HHS Lets Pharmacies Compound Six Unapproved Peptides; What's Really Mixed Into Compounded GLP-1s
- Wednesday, October 28, 2026 · 7 min Fewer Employers Cover GLP-1s for Weight Loss in 2027; Walgreens Adds Coverage Help; Vanda Reports Phase 3 Data on a GLP-1 Anti-Vomiting Pill
- Tuesday, October 27, 2026 · 7 min Judge Lets Lilly Keep Its Zepbound-vs-Wegovy Ads Running; South Korea Puts Obesity Drugs Up for Insurance Review; Dr. Reddy's Targets a November Semaglutide Restart
- Monday, October 26, 2026 · 7 min South Africa's Regulator Says Bulk Compounders Are Manufacturing; Belgium Won't Pay for Mounjaro in Obesity; Who Started the Wegovy Pill
- Friday, October 23, 2026 · 7 min Mass General Brigham Drops Weight-Loss GLP-1 Coverage for Some Staff; MPs Call NHS Mounjaro Plan 'Woefully Small'; CBS Tests Bootleg Retatrutide
- Thursday, October 22, 2026 · 6 min Judge Sends Zepbound Denial Suit to Arbitration; Telehealth Sells GLP-1s for Addiction; SOUL's Kidney Fine Print
- Wednesday, October 21, 2026 · 7 min Houston Pharmacy Recalls Compounded Tirzepatide After FDA Sterility Findings; Belgium Warns on Off-Label Use
- Monday, October 19, 2026 · 7 min FDA Blocks Two Chinese GLP-1 Ingredient Makers; Obesity-Drug Denials Get Harder to Beat
- Wednesday, October 14, 2026 · 6 min Death Reports Name Bootleg Retatrutide; Walmart's Free GLP-1s Skip Weight Loss
- Tuesday, October 13, 2026 · 6 min Retatrutide Black Market Hits Before Approval; Wegovy Pill Generics Far Off
- Monday, October 12, 2026 · 4 min Wegovy Liver-Fat Data at EASD 2026, and What the Wegovy Pill Changes
- Friday, October 9, 2026 · 6 min Lilly's Oral GLP-1 Orforglipron Clears Heart-Safety Bar in ACHIEVE-4
- Thursday, October 8, 2026 · 11 min GLP-1 Users Lost Sight in the Second Eye Sooner, Ophthalmology Study Finds as Vision-Loss Lawsuits Grow
- Wednesday, October 7, 2026 · 5 min Medicare's $50 GLP-1 Bridge Leaves Out Some Sick Seniors
- Tuesday, October 6, 2026 · 11 min Federal Plans Tie 2027 GLP-1 Coverage to Behavioral Therapy as Diabetes Guidelines Move GLP-1s Up Front
- Monday, October 5, 2026 · 10 min Rhode Island Joins the Medicaid GLP-1 Cutbacks as Massachusetts Weight-Loss Use Falls 52%
- Friday, October 2, 2026 · 10 min A $75 Copay Cliff for GLP-1 Adherence as New Mexico's Medicaid Ozempic Bill Climbs
- Thursday, October 1, 2026 · 10 min Zepbound Returns to CVS Caremark as Massachusetts Faces Equity Pushback on GLP-1 Cuts
- Wednesday, September 30, 2026 · 9 min Counterfeit Ozempic Indictment Lands as Retatrutide Data Hits EASD
- Tuesday, September 29, 2026 · 9 min Zealand, Roche Start Petrelintide Phase 3 as 100% Pharma Tariffs Begin
- Monday, September 28, 2026 · 7 min Mylan Tests Novo's Wegovy Patents as States Target Chinese GLP-1 Supply
- Friday, September 25, 2026 · 8 min Mounjaro Misuse in Japan, Contraband GLP-1 Pens Flood Brazil
- Thursday, September 24, 2026 · 9 min Semaglutide heart signal meets FDA import and Medicare access shifts